THANK YOU FOR SUBSCRIBING
Immunoscore has a high prognostic value in this new indication. It may help promote a consistent change in clinical strategy: organ preservation in patients with locally advanced rectal cancer who have a positive prognosis.
FREMONT, CA: HalioDx SAS, the immuno-oncology diagnostics firm pioneering the immunological diagnosis of cancers, announced that Immunoscore is now available through an Innovation Access Program for the management of Locally Advanced Rectal Cancer (LARC). Immunoscore has a high prognostic value in this new indication. It may help promote a consistent change in clinical strategy: organ preservation in patients with locally advanced rectal cancer who have a positive prognosis.
Dr. John Low Seng Hooi, MBBS, MRCP, FRCR, FRCP, FAMS, AM, Clinical Oncologist at Pantai Hospital Kuala Lumpur, Malaysia, added: “To complete clinical assessment, Immunoscore could rapidly become the precision tool we need for supporting our clinical decisions. We are delighted to implement Immunoscore in our practice through this Innovation Access Program with HalioDx.”
Dato Dr. Meheshinder Singh, founder of the Colorectal Cancer Survivorship Society Malaysia, and past President of the Malaysian Society of Colorectal Surgeons, Colorectal surgeon at Pantai Hospital Kuala Lumpur, Malaysia, commented: Colorectal Cancer is the most common cancer in men and number two cancer in women in Malaysia. At PHKL, we are deeply committed to improving quality of care in locally advanced rectal cancer patients.”
Immunoscore is an independent parameter that is more informative than pre- and post-neoadjuvant treatment imaging for predicting disease-free survival in rectal cancer, where no standardized biomarker is available to personalize treatment.
El Sissy et al. recently published a study in Clinical Cancer Research that looked at whether Immunoscore could predict neoadjuvant treatment response in different LARC patient cohorts and a validation “Watch and Wait” cohort. Immunoscore combined with imaging post-neoadjuvant care will distinguish patients who have a full clinical response and may benefit from the organ preservation strategy, according to the researchers. Surprisingly, virtually all patients with a high Immunoscore in the “Watch and Wait” cohort had a positive answer to therapy and prevented relapse.
Vincent FERT, CEO of HalioDx, concluded: “We are very pleased to partner with oncologists, surgeons and pathologists committed to advance locally advanced rectal cancer patient management. Our Innovation Access Program leverages our Immunoscore technology platform, already in the ESMO guidelines for colon cancer, that measure the host immune response at the tumor site in a spatially resolved manner enabling informed medical decisions.”